Compare prices and buy Tesofensine from 11 research peptide vendors - also called suppliers or sources. Updated daily.
Tesofensine is a phenyltropane small molecule, not a peptide, that inhibits presynaptic reuptake of serotonin, noradrenaline and dopamine. It is catalogued here because peptide vendors sell it alongside their peptide catalogs. It is not FDA-approved, and a marketing application for obesity in Mexico has not been approved.
For research purposes only. Not medical advice.
Tesofensine is not a peptide. It is a small molecule, a dichlorophenyl-substituted tropane with the formula C17H23Cl2NO and a molecular weight of 328.3, and CAS 195875-84-4 is its free base, matching the FDA substance record (UNII BLH9UKX9V1). It sits in Experimental because peptide vendors sell it beside their peptide catalogs, a commercial overlap with no chemical kinship behind it. In early development it carried the code NS2330.
Tesofensine inhibits the presynaptic reuptake of noradrenaline, dopamine and serotonin. Saniona, which now holds the program, describes the result as raised levels of those three neurotransmitters, which are involved in appetite regulation, food-seeking behavior and metabolism. That central monoamine mechanism is unrelated to the GLP-1 receptor agonism of semaglutide and the other compounds in GLP Agonist & Weight Loss.
Tesofensine was first developed for neurodegenerative disease. ClinicalTrials.gov lists completed Phase 2 trials of NS2330 in Parkinson's disease, sponsored by the National Institute of Neurological Disorders and Stroke from 2000 and by Boehringer Ingelheim from 2003, and one in Alzheimer's disease sponsored by Boehringer Ingelheim.
A 2008 pooled analysis in Obesity (Astrup et al.) combined four of those randomized, double-blind trials, two in each disease, with 740 patients on tesofensine and 228 on placebo over 14 weeks and no weight-loss program. Body weight fell as the dose rose, from a 0.5% gain on placebo to a 2.8% loss in the highest arm. Heart rate rose by as much as 6.8 beats per minute across the arms, with no effect on blood pressure observed. The authors wrote that the compound was now being developed for obesity.
In obesity, NeuroSearch sponsored a Phase 2 trial published in The Lancet in 2008 (Astrup et al., ClinicalTrials.gov NCT00394667), which Saniona's reports call TIPO-1. At five Danish obesity centres, 203 patients with a body-mass index of 30 to 40 were put on an energy-restricted diet and randomized to one of three tesofensine doses or placebo for 24 weeks. Of those, 161 (79%) completed it.
Counting randomized patients with a measurement after at least one dose (modified intention to treat), mean weight loss was 4.5% to 10.6% across the three tesofensine arms against 2.0% with diet and placebo. The most common adverse events were dry mouth, nausea, constipation, hard stools, diarrhoea and insomnia. Systolic and diastolic blood pressure showed no significant rise over placebo in the two lower-dose arms, and heart rate rose by 7.4 beats per minute in the middle arm. The authors wrote that the efficacy and safety findings needed confirmation in Phase 3 trials.
Saniona later paired the compound with metoprolol, a beta-1 receptor blocker, in a fixed-dose combination called Tesomet. ClinicalTrials.gov lists its Phase 2 trials in type 2 diabetes, Prader-Willi syndrome and hypothalamic injury-induced obesity as completed, and two later Phase 2 records as withdrawn.
As of October 21, 2026, Drugs@FDA returns no application for tesofensine, so it holds no FDA approval and is not a component of any approved drug. It appears in neither of FDA's bulk-substance nomination lists (503A, updated May 14, 2026, and 503B, updated March 21, 2025), so neither a 503A compounding pharmacy nor a 503B outsourcing facility can use it. In a December 2025 warning letter to an API distributor, the FDA listed tesofensine among substances ineligible for use in human drug compounding under section 503A.
It is also absent from both tables of the FDA's Category 2 safety-risk page and from the July 2026 Pharmacy Compounding Advisory Committee agenda, so the arc traced on the BPC-157 page does not apply to it.
In Mexico, Saniona's partner Productos Medix applied to COFEPRIS, the Mexican regulator, for approval in obesity, on the basis of what Saniona describes as a 24-week, placebo-controlled Phase 3 trial in 372 patients. A COFEPRIS technical committee issued a favorable non-binding opinion in February 2023. Saniona announced on November 6, 2024 that the Mexican application was not yet approved, and on February 20, 2025 that Medix had resubmitted the dossier. Saniona's year-end report for 2025 described the application as under review, and its interim report for the second quarter of 2026 says Medix continues to pursue regulatory approval.
As of October 2026, every tesofensine listing PeptideScouter indexes is an oral capsule or tablet, sized as a count of units at a per-unit strength labeled in micrograms. Vendors write that strength in micrograms or as a decimal fraction of a milligram, so two titles can name the same strength in different units. Per-milligram figures compute only for vials, so these listings are indexed but absent from every $/mg comparison.
No. Tesofensine is a small molecule, a dichlorophenyl-substituted tropane with the formula C17H23Cl2NO and a molecular weight of about 328, while peptides are chains of amino acids. It is catalogued on PeptideScouter because research vendors sell it beside their peptide catalogs, a commercial overlap with no chemical kinship behind it.
As of October 2026, every tesofensine listing PeptideScouter indexes is an oral capsule or tablet whose strength is labeled in micrograms per unit. PeptideScouter computes a per-milligram price only for vials sized in milligrams, so these listings show their vendor prices but are left out of every per-milligram comparison. A capsule or tablet listing is sized as a count of units at a stated strength, which is not one vial mass.
TIPO-1 was a 24-week Phase 2 trial sponsored by NeuroSearch and published in The Lancet in 2008. It randomized 203 patients with obesity, all on an energy-restricted diet, to one of three tesofensine doses or placebo. Counting randomized patients with a measurement after at least one dose, mean weight loss was 4.5% to 10.6% across the tesofensine arms and 2.0% with placebo. The most common adverse events were dry mouth, nausea, constipation, hard stools, diarrhoea and insomnia, and heart rate rose by 7.4 beats per minute in one tesofensine arm. The authors said the findings needed confirmation in Phase 3 trials.
No. No FDA-approved drug contains tesofensine, and as of October 2026 it appears in neither of FDA's bulk drug substance nomination lists, the one for 503A compounding pharmacies or the one for 503B outsourcing facilities. In a December 2025 warning letter to an API distributor, the FDA listed tesofensine among substances ineligible for use in human drug compounding under section 503A.
Tesomet is Saniona's fixed-dose combination of tesofensine with metoprolol, a beta-1 receptor blocker. Saniona describes it as an investigational therapy for hypothalamic obesity and Prader-Willi syndrome. ClinicalTrials.gov lists its Phase 2 trials in type 2 diabetes, Prader-Willi syndrome and hypothalamic injury-induced obesity as completed, and two later Phase 2 records as withdrawn.
Tesofensine is sold by 11 research peptide vendors indexed on PeptideScouter, with 11 tracked listings compared per vendor in the table above. Pricing is normalized and refreshed daily.
8 of the 11 indexed vendors currently have Tesofensine in stock. The comparison table marks out-of-stock listings, and stock state is refreshed daily.
Discount codes are issued per vendor rather than per peptide, so any code applies across that vendor's whole catalog. All 11 vendors listing Tesofensine publish a PeptideScouter code, worth 10% to 15% off. These listings do not carry a comparable per-milligram price, so code availability is shown without a normalized effective price. Each vendor's code is shown beside its price in the table above.
11 research peptide vendors currently list Tesofensine on PeptideScouter, with 8 in stock right now. We track 11 listings across size and kit variants.
Tesofensine's CAS Registry Number is 195875-84-4. It is also sold as Tesofensine.
